Condensed Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (13,692,944)	$ (9,836,670)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	202,971	388,777
Amortization	12,173	2,906
Amortization of right-of-use assets	438,601	274,158
Loss on disposal of assets	0	44,538
Accounts receivable reserve	6,000	0
Inventory reserve	2,830	4,972
Share-based compensation expense	310,004	626,529
Amortization of debt issuance costs and discount	854,902	0
Changes in operating assets and liabilities:
Accounts receivable	(285,384)	(26,086)
Inventory	(1,273,382)	(170,917)
Prepaid and other assets	(266,518)	313,154
Accounts payable	(51,799)	341,119
Accrued expenses	(316,651)	112,728
Lease liabilities	(273,734)	(304,004)
Other liabilities	(36,509)	(15,770)
Net cash used in operating activities	(14,369,440)	(8,244,566)
Cash flows from investing activities:
Acquisition of patents	(82,237)	0
Purchases of property and equipment	(654,914)	(99,018)
Net cash used in investing activities	(737,151)	(99,018)
Cash flows from financing activities:
Proceeds from the issuance of common stock and warrants in April 2023 Financing	0	3,899,813
Equity issuance costs for April 2023 Financing	0	(547,764)
Proceeds from exercise of pre-funded warrants	0	188
Proceeds from exercise of common warrants	0	1,059,975
Proceeds from common stock issued through ESPP and exercised options	10,390	1,697
Proceeds from at-the-market sales of common stock	1,021,994	3,373
Issuance costs for at-the-market sales of common stock	(30,660)	0
Repayment of note payable	0	(327,006)
Payments under lease obligations	0	(16,193)
Net cash provided by financing activities	1,001,724	4,074,083
Net change in cash and cash equivalents	(14,104,867)	(4,269,501)
Cash and cash equivalents:
Beginning of period	21,716,077	12,961,936
End of period	7,611,210	8,692,435
Cash paid for:
Interest	0	9,903
Taxes	5,708	4,550
Non-cash investing and financing activities:
Property and equipment costs included in accounts payable and accrued expense	35,849	0
Commissions costs relating to certain proceeds from issuance of common stock	0	6,163
Deferred offering costs reclassified to additional paid-in-capital	1,586	0
Right-of-use asset obtained in exchange for a lease liability	0	2,496,968
Prepaid insurance financed with promissory notes	$ 0	$ 283,334